@article{f0e07c6a1dc94904a11baacfc11ec05c,
title = "Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy",
abstract = "Kaneko et al. describe the effective generation of antigen-specific T cell receptor-stabilized CD8αβ T cells from T cell-derived or monocyte-derived iPSCs, both with genetic modification at the iPSC stage. Those T cells showed monoclonal expression of desired TCR and effectively inhibited tumor growth in xenograft cancer models.",
keywords = "antigen-specific T cell regeneration, cancer immunotherapy, CD8 T cell, cytotoxic T cell, HLA matched iPS cell, iPS cell bank, T cell differentiation, T cell-derived iPS cell, TCR gene therapy, TCR rearrangement",
author = "Atsutaka Minagawa and Toshiaki Yoshikawa and Masaki Yasukawa and Akitsu Hotta and Mihoko Kunitomo and Shoichi Iriguchi and Maiko Takiguchi and Yoshiaki Kassai and Eri Imai and Yutaka Yasui and Yohei Kawai and Rong Zhang and Yasushi Uemura and Hiroyuki Miyoshi and Mahito Nakanishi and Akira Watanabe and Akira Hayashi and Kei Kawana and Tomoyuki Fujii and Tetsuya Nakatsura and Shin Kaneko",
note = "Funding Information: S.K. is a founder, shareholder, and chief scientific officer at Thyas Co., Ltd. and received research funding from Takeda Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Sumitomo Chemical Co., Ltd., and Thyas Co., Ltd. M.N. is a founder, shareholder, and chief technical officer at Tokiwa-bio Co., Ltd. T.N. is a founder and shareholder at Killer T Save You Co., Ltd. M.K., M.T., Y. Kassai, and A. Hayashi are employees of Takeda Pharmaceutical Co. Ltd. Y.Y. is an employee of Thyas Co. Ltd. The remaining authors declare no competing financial interests. Funding Information: We thank Prof. Shinya Yamanaka (Kyoto University) for providing the HLA homozygous iPSC line and giving critical advice for our research work. We thank Prof. Hiromitsu Nakauchi (The University of Tokyo) and Prof. Naoko Takasu (Kyoto University) for providing the iPSC lines; Dr. Seigo Izumo (T-CiRA) for giving critical advice; Prof. Michio Tomura (Osaka Otani University) for live imaging technique; Drs. Tatsuki Ueda, Yuta Mishima, Wang Bo, and Hisashi Yano (Kyoto University); Hiroshi Fujiwara and Toshimoto Ochi (Ehime University); Keiko Koga, Takayuki Sato, Masashi Yamada, and Sujatha Mohan (T-CiRA); Messrs. Shuichi Kitayama, Kohei Ohara, and Akito Tanaka (Kyoto University); Tokuyuki Shinohara, Kazuhide Nakayama, Suguru Arima, and Yuji Baba (T-CiRA); Mses. Ayako Kumagai, Sanae Kamibayashi, and Hitomi Takakubo (Kyoto University); Mariko Sekiguchi, Maki Numazaki, Yuka Maruyama, Yuki Watanabe, and Ai Kikuchi (T-CiRA) for technical assistance. We thank Dr. Peter Karagiannis (Kyoto University) for editing the manuscript. The entire study was conducted in accordance with the Declaration of Helsinki and permitted by the institutional ethical board of Kyoto University. This work was supported in part by the Ministry of Education, Culture, Sports, Science and Technology Japan ( 23591413 , 15H04655 , 15J05263 , and 26293357 ), Japan Agency for Medical Research and Development (Project for Development of Innovative Research on Cancer Therapeutics, Practical Research for Innovative Cancer Control, and Core Center for iPS Cell Research), the Takeda-CiRA collaboration program, collaborative research grant of Thyas Co., Ltd., and National Cancer Center Research Fund . Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",
year = "2018",
month = dec,
day = "6",
doi = "10.1016/j.stem.2018.10.005",
language = "English",
volume = "23",
pages = "850--858.e4",
journal = "Cell Stem Cell",
issn = "1934-5909",
publisher = "Cell Press",
number = "6",
}
